Coronary Stents Market

Coronary Stents Market Size, Market Forecast and Outlook By FMI

The coronary stents market is expected to expand from USD 37.5 billion in 2026 to USD 64.6 billion by 2036. The market is anticipated to register 5.6% CAGR during the forecast period as PCI procedures retain an important role in coronary artery disease treatment. Drug-eluting stents are likely to lead with 33.2% share in 2025 and hospitals are projected to account for 27.1% share in 2025.

Summary of the Coronary Stents Market

• Demand and Growth Drivers
  • High cardiovascular disease incidence is expected to sustain procedure demand across catheterization laboratories and interventional cardiology departments.
  • Preference for minimally invasive revascularization is anticipated to lift stent use among patients needing faster recovery after PCI.
  • Clinical use of improved DES platforms is likely to reduce restenosis concerns and strengthen physician confidence in complex lesion treatment.
• Product and Segment View
  • Drug-eluting stents are expected to lead product demand as medication release helps manage scar tissue formation after implantation.
  • Hospitals are likely to keep the leading end user position since advanced cath labs handle complex cardiac interventions.
  • Bioabsorbable stents are anticipated to gain physician attention as scaffold designs improve temporary vessel healing and long-term safety profiles.
• Geography and Competitive Outlook
  • The United States is expected to keep a significant value share through premium reimbursement and advanced PCI procedure capacity.
  • Italy is likely to record the fastest listed country CAGR as hospital access and cardiac procedure use improve steadily.
  • Large device companies are anticipated to compete through flexible DES delivery systems and better clinical evidence for bioresorbable scaffolds.
• Analyst Opinion
  • Sabyasachi Ghosh, is Principal Consultant for Healthcare at FMI and suggests, “The coronary stents market is expected to favor manufacturers with strong DES portfolios and credible scaffold data. Hospitals are likely to prefer platforms backed by evidence across complex coronary anatomy and predictable post-procedure outcomes.”
• Coronary Stents Market Value Analysis
  • The coronary stents market is moving from established metallic devices toward a broader mix of DES and bioresorbable scaffolds.
  • Demand is likely to increase as coronary artery disease burden keeps PCI procedures central to interventional cardiology practice.
  • Adoption is expected to rise through low-profile delivery systems designed for multi-vessel disease and difficult coronary anatomy.
  • Spending is anticipated to be shaped by premium reimbursement access and longer clinical validation requirements for advanced stent platforms.

Key Takeaways, Market Size, and Forecast

• The coronary stents market is expected to reach USD 37.5 billion in 2026 as PCI procedures continue across major healthcare systems.
• By 2036, the coronary stents market is projected to reach USD 64.6 billion as DES use and scaffold adoption broaden.
• From 2026 to 2036, the market is anticipated to expand at 5.6% CAGR across global healthcare systems.
• Drug-eluting stents are likely to account for 33.2% share of the product type segment in 2025.
• Hospitals are expected to hold 27.1% share of the end user segment in 2025 across the global market.
• Italy is projected to record the fastest listed country-level expansion at 2.9% CAGR through 2036.

Summary of Coronary Stents Market

What Is Growth Outlook for Coronary Stents Market as per Future Market Insights Projection?

Future Market Insights projects the coronary stents market to expand at a CAGR of 5.6% from 2026 to 2036, increasing from USD 37.5 Billion in 2026 to USD 64.6 Billion by 2036.

FMI Research Approach: FMI proprietary forecasting model based on PCI procedure volumes and DES/BVS adoption rates.

How Do FMI Analysts Perceive Coronary Stents Market to Evolve?

FMI analysts perceive the market evolving toward a dual-platform structure where established metallic DES systems continue as the high-volume standard while bioresorbable scaffolds gain share in select complex lesion applications.

FMI Research Approach: MicroPort Firesorb BVS launch (September 2025) and Abbott XIENCE Sierra clinical data.

Which Country Holds Largest Share in Global Coronary Stents Market?

The United States holds a significant share of the global coronary stents market by value, which is supported by the highest per-capita PCI procedural rate and premium reimbursement for next-generation DES platforms.

FMI Research Approach: FMI country-level revenue modeling by PCI procedure volumes and CMS reimbursement rates.

How Large Will Coronary Stents Market Be by 2036?

The global coronary stents market is projected to reach USD 64.6 Billion by 2036.

FMI Research Approach: FMI long-term revenue forecast derived from WHO cardiovascular disease burden projections and PCI volume growth rates.

What Is Definition of Coronary Stents Market?

The coronary stents market includes revenue from drug-eluting stents (DES), bare-metal stents (BMS), and bioresorbable vascular scaffolds (BVS) used in percutaneous coronary intervention procedures for coronary artery disease treatment.

FMI Research Approach: FMI market taxonomy aligned with FDA and CE-mark device classifications.

What Are Globally Unique Trends Shaping Coronary Stents Market?

Globally unique trends include the re-emergence of bioresorbable scaffold technology with improved clinical outcomes, the launch of ultra-low-profile DES platforms for complex anatomies, and the prioritization of emerging markets for new stent introductions.

FMI Research Approach: MicroPort Firesorb launch (September 2025) and Abbott XIENCE Sierra India launch (May 2024).

Coronary Stents Market Key Takeaways

Metric	Details
Industry Size (2026)	USD 37.5 Billion
Industry Value (2036)	USD 64.6 Billion
CAGR (2026 to 2036)	5.6%

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

Segment-wise Analysis

By Product

Attributes	Details
Top Source Type	Drug-Eluting Stents (DES)
Market Share in 2025	33.2%

Drug-eluting stents (DES) is expected to account for a leading coronary stent market share of 33.2% in 2025. The Drug Eluting Stent has the capability to prevent the risks of restenosis (the process of the arteries getting smaller again), which is known to be caused by scar tissue, and it does this by means of drugs that prevent the production of the scar tissue. The rise in coronary artery disease, which is a common health problem, has resulted in a demand for the newest stent technologies like DES. These particular types of stents perform better in challenging cases of surgery.

By End User

Attributes	Details
Top Source Type	Hospitals
Market Share in 2025	27.1%

Hospitals are poised to occupy 27.1% of the coronary stents market in 2025 due to the advanced clinical facilities. Hospitals, particularly the larger medical center types, are outfitted with the newest equipment and have specialized cardiology departments, therefore, they are the best choice for complex heart procedures.

On the other hand, the adoption of new technologies by manufacturing for stent models ensures the production of higher quality products while minimizing environmental impact, waste generation, energy consumption, and other costs. Hospitals primarily offer after-procedure care like dosage control, angiogram as a follow-up treatment, and lifestyle changes advice which together, help in the recovery of patients and also promote the stay of the stents in the bodies of the patients, especially in the healthcare systems that are good.

Key Drivers

High Prevalence of Cardiovascular Diseases Pushes the Demand for Minimally Invasive Procedures

Cardiovascular diseases (CVDs) have become more common worldwide, and the need for coronary stents has grown exponentially, throughout the years of the pandemic. The predominant risk factors are poor diet, smoking, sedentary lifestyle, and stress. According to World Health Organization (WHO) CVDs are primarily responsible for premature deaths among the population with about 18 million fatalities every year.

The coronary stent sector is seeing technological progress with items like drug-eluting stents (DES) which are capable of discharging medicine meant to obstruct restenosis, biodegradable stents that erode after a certain period of time, and state-of-the-art imaging equipment like OCT (optical coherence tomography) which comes in handy for proper stent placement.

Technological Advancements in Stent Design Improves Patient Outcomes

Technological advancements in stent design are significantly improving patient outcomes. Drug-eluting stents (DES) release medication that prevents tissue overgrowth, reducing restenosis rates compared to traditional bare-metal stents. Bioabsorbable stents, which dissolve over time, offer the advantage of eliminating long-term complications.

Additionally, advanced coatings have improved biocompatibility and minimizes the risks of stent thrombosis. Healthcare providers have turned to coronary stents due to different innovations in the sector such as Drug Eluting Stents, Biodegradable Stents and Bioresorbable Vascular scaffolds which give higher effectivity and safety.

Stringent Regulatory Approval Processes Challenges Product Launch Strategies

Aspect	Details
Complex Regulations	Coronary stents are objects that are directly placed inside the human body. They are strictly bound to the safety and efficacy standards. From a regulatory aspect organizations such as FDA (USA), EMA (Europe), and CDSCO (India), underlines extensive clinical trials and tight testing to be conducted prior any approval. A manufacturer undergoing the approval period often faces a complex procedure that might negatively impact their market entry.
Cost of Compliance	Significant expenditure is involved in compliance with regulatory standards that often impacts the overall operations. It is imperative that production enterprises incur cost investments for research, clinical trials, and meet sustainability standards. The aforementioned factors may be the rationale for the high overall product price and postponement of the product launch.
Regional Variations	The cross-market strategies of companies are hampered by regional variances in disease prevalence, health care systems and economic factors thus rendering it harder for companies to implement the same strategies across the board. They have to tailor their products, pricing, and regulations to the requirements of every market.
Impact	The strict regulatory framework can slow innovation and limit the availability of new products. For smaller manufacturers, the barriers to entry can restrict competition, ultimately affecting the variety of treatment options available to patients.

High Costs and Limited Accessibility Hinders Availability

Aspect	Details
Pricing Challenges	The pricing of state-of-the-art coronary stents, especially drug-eluting and bioabsorbable is on the higher side as they involve advanced technology and materials. These elevated prices make the products unaffordable thus, stents are inaccessible to many parts of the population, particularly in underdeveloped countries and even some middle-income countries. The costs involved can influence patient decision to choose stent therapies.
Reimbursement Limitations	Reimbursement restrictions manifested in the coronary stents market due to the existence of different healthcare policies in different areas, which frequently set restrictions on the use of high-cost stents like drug-eluting and biodegradable ones. These limitations cause patients to be dependent on cheaper bare-metal stents thus, affecting the market growth for CRT and innovative technologies.
Health Disparities	Rural or underserved spaces often lack access to high-end cardiac care including stent implantation. The deficit of adequate resources and capital is the main reason for the increased obstructions in healthcare in these areas. Hence, the population from such areas lack access to life-saving techniques leading to fatality from cardiovascular diseases.
Impact	The capacity of advanced cardiac care like stenting is very low in rural and underserved parts.. The absence of necessary facilities and qualified personnel in these parts is the major reason why healthcare disparities are so acute..

Key Trends

The increasing acceptance of bioabsorbable stents (also referred to as bioresorbable vascular scaffolds or BVS) is a notable trend. These state-of-the-art stents outperform conventional permanent stents in terms of dissolving cells over time, which results in no permanent implant in the body.

• Biodegradability & Temporary Support: Contrary to permanent stents, bioabsorbable stents offer temporary support to the artery, allowing it to replenish itself naturally. This helps to avoid future complications such as chronic inflammation, late stent thrombosis, and vessel restenosis that could occur due to the stiff nature of traditional stents.
• Improved Patient Outcomes: Because they do not involve a permanent implant, bioabsorbable stents eliminate the risk of complications and instead foster the proper function of the artery which, in turn, accelerates the restoration of normal vascular function and flexibility.
• Technological Advancements: Progresses in materials (e.g., polylactic acid or magnesium alloy) is improving the performance of bioabsorbable stents. Drug-eluting coatings are also added to enhance effectiveness and reduce the rate of restenosis.
• Research and Development Surge: The primary companies such as Abbott Laboratories and Boston Scientific are set to provide massive sums in support for the development of next-gen bioabsorbable stents.
• Market Expansion: The rapid growth of bioabsorbable stents at a faster rate compared to other stent types is anticipated due to the increasing number of patients' requests for such devices and the approval from regulatory authorities.

Country-wise Analysis

Countries	CAGR
The USA	1.5%
Canada	2.7%
Germany	1.6%
France	2.4%
Italy	2.9%
UK	1.9%

The USA dominates the coronary stents market with a sizeable share of global sales. Factors such as availability of an advanced medical care system and the high prevalence of cardiovascular diseases (CVDs) in the population. The popularity of drug-eluting and bioabsorbable stents is leading to high demand.

Abbott Laboratories and Boston Scientific are significantly invest in innovations in the field of high-technology drug-eluting stents, bioresorbable stents, and next-gen imaging devices, particularly. Abbott's Xience drug-eluting stent and Boston Scientific's Synergy stent are both, demonstrating the development methods for the leading-edge innovation of coronary stents.

Researchers and manufacturers are focusing on combining imaging, stent technology, and personalized medicine to improve outcomes. This includes developing advanced imaging tools for better stent placement and creating stents tailored to individual patient needs.

Europe is the fast-growing market thanks to its advanced healthcare system and a high rate of lifestyle-related health issues, Germany is leading the European coronary stents market. The government and the private companies are dedicated to improving medical devices through innovation by provide funding, resources, and incentives to support the development of new technologies in healthcare. Angioplasty and stent procedures are widely accessible through health insurance.

Competitive Landscape

The coronary stent market has made impressive strides of progress throughout the past years in factors such as new product launches, market entrants, and the changing regulatory landscape.

Elunir-Perl Drug-Eluting Stent by Medinol

Elunir-Perl was FDA approved in October 2023 and is a new stent for coronary artery disease that is designed to provide patients with a safe and effective treatment.

Xience Sierra by Abbott Laboratories

Xience Sierra was FDA approved in 2018 and is a drug-eluting stent which features a lower profile and better flexibility and is produced in small diameters and longer lengths. It's meant to assist complex percutaneous coronary interventions (PCI), thus aiding in a better patient outcome.

Resolute Onyx 2.0mm by Medtronic

Resolute Onyx 2.0mm was FDA approved in 2018. It is a tiny drug-eluting stent that is made for patients with small coronary arteries thus making it more effective in treating the problems of patients with complicated anatomy.

Recent Developments

• In September 2025, MicroPort launched Firesorb, its next-generation bioresorbable vascular scaffold, following successful multi-year clinical follow-ups in the FUTURE study series.
• In May 2024, Abbott launched its latest-generation XIENCE Sierra drug-eluting stent in India, featuring an ultra-low profile and high-flexibility delivery system for complex coronary anatomies.
• Boston Scientific reported that 2025 was an exceptional performance year with its interventional cardiology division delivering differentiated innovation that exceeded growth targets.

Emerging Startups and Innovations

Emerging startups are driving the advancement of bioresorbable stent technology; they are now targeting next-generation solutions, which are the ones that naturally dissolve in the body; this way, there is no need for permanent implants. These stents are a safe alternative to metal stents as they prevent complications like late stent thrombosis and are actually safer than traditional metal stents. A few notable companies in the field include:

• BIOTRONIK: This medical technology company is making advancements in bioresorbable vascular scaffolds, which, as per the reports of 2024, have been subjected to successful clinical trials and have also received regulatory approvals. The company desires to aid in the recovery of patients with coronary artery disease by vascular repair function while decreasing long-term problems.
• Reva Medical: The leading promoter of bioresorbable vascular scaffolds, Reva Medical, has established its Fantom scaffold in more international markets. In 2024, the company formed a partnership with the material science department at the local university to research and develop a more substantial material and better resorption rate, thereby facilitating their stent technology.
• Arterial Remodeling Technologies (ART): ART has built a considerable base on bioresorbable stent platforms and, in 2024, grew considerably after obtaining significant funding. Their mission is to polish, i.e., improve stent effectiveness, thus leading to healthier arteries in the long term.

Key Market Players

• TERUMO CORPORATION
• Boston Scientific Corporation
• Medtronic
• Vascular Concepts
• B. Braun Melsungen AG
• BIOTRONIK SE & Co. KG
• Abbott Laboratories
• Biosensors International Group, Ltd.
• HEXACATH
• STENTYS SA

Market Definition

The coronary stents market represents revenue generated from implantable coronary artery stents and scaffolds used in percutaneous coronary intervention (PCI) procedures. The market measures the value of drug-eluting stents, bare-metal stents, and bioresorbable vascular scaffolds sold to hospitals, catheterization laboratories, and interventional cardiology centers.

Inclusions cover drug-eluting stents (polymer-coated and polymer-free), bare-metal stents, bioresorbable vascular scaffolds, and dual-therapy stents. It includes balloon-expandable and self-expanding delivery systems. Dedicated PCI guidewires and inflation devices bundled with stent systems are also included.

Exclusions include peripheral vascular stents, carotid stents, structural heart devices such as TAVR valves, and standalone PCI diagnostic equipment. Coronary artery bypass graft (CABG) surgical instruments and standalone angiography systems are outside the scope.

Scope of Report

Items	Values
Quantitative Units (2026)	USD 37.5 Billion
Product Type	Drug-Eluting Stents, Bare-Metal Stents, Bioresorbable Vascular Scaffolds
Material Type	Cobalt-Chromium, Platinum-Chromium, Stainless Steel, PLLA Bioresorbable
End User	Hospitals, Catheterization Laboratories, Interventional Cardiology Centers
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Key Companies Profiled	Boston Scientific, Abbott, Medtronic, MicroPort, B. Braun, Terumo

Segmentation

By Product:

Drug Eluting Stents (DES), Bare Metal Stents (BMS), Bioabsorbable Stents, Self-expanding Stents, Balloon-expandable Stents, etc.

By End User:

Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other Healthcare Settings.

By Raw Material:

Cobalt-Chromium, Stainless Steel, Platinum-Chromium, Nickel-Titanium, Polymer

By Region:

North America, Latin America, Western Europe, South Asia and Pacific, East Asia, Middle East and Africa.

Bibliography

• MicroPort Scientific Corporation. (2025, September). Firesorb bioresorbable vascular scaffold launch and FUTURE study results. MicroPort Press Releases.
• Abbott Laboratories. (2024, May). XIENCE Sierra drug-eluting stent India launch. Abbott Newsroom.
• Boston Scientific Corporation. (2026, February). Fourth quarter and full year 2025 results. Boston Scientific Investor Relations.
• World Health Organization. (2024). Cardiovascular diseases fact sheet. WHO.